AMI Asset Management Corp Sells 12,087 Shares of Zoetis Inc. $ZTS

AMI Asset Management Corp cut its holdings in Zoetis Inc. (NYSE:ZTS) by 3.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 302,152 shares of the company’s stock after selling 12,087 shares during the quarter. Zoetis makes up 2.5% of AMI Asset Management Corp’s portfolio, making the stock its 16th largest position. AMI Asset Management Corp owned 0.07% of Zoetis worth $44,211,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its position in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after purchasing an additional 2,978 shares in the last quarter. Ieq Capital LLC increased its holdings in shares of Zoetis by 23.9% in the first quarter. Ieq Capital LLC now owns 33,918 shares of the company’s stock valued at $5,585,000 after purchasing an additional 6,541 shares in the last quarter. CreativeOne Wealth LLC raised its position in Zoetis by 9.0% in the 1st quarter. CreativeOne Wealth LLC now owns 16,053 shares of the company’s stock worth $2,643,000 after purchasing an additional 1,321 shares during the last quarter. Cape ANN Savings Bank lifted its holdings in Zoetis by 7.3% during the 1st quarter. Cape ANN Savings Bank now owns 5,040 shares of the company’s stock worth $830,000 after buying an additional 341 shares in the last quarter. Finally, Oarsman Capital Inc. boosted its position in Zoetis by 7.4% in the 1st quarter. Oarsman Capital Inc. now owns 1,913 shares of the company’s stock valued at $315,000 after buying an additional 132 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of recent research reports. UBS Group dropped their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research report on Wednesday, November 5th. Argus restated a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. HSBC set a $140.00 target price on shares of Zoetis in a research note on Wednesday, December 10th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Finally, Weiss Ratings cut shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Zoetis currently has an average rating of “Hold” and an average target price of $160.18.

Zoetis Price Performance

ZTS stock opened at $125.50 on Friday. The stock has a 50-day moving average price of $127.41 and a two-hundred day moving average price of $143.41. Zoetis Inc. has a 1 year low of $115.25 and a 1 year high of $177.40. The stock has a market cap of $55.31 billion, a PE ratio of 21.13, a price-to-earnings-growth ratio of 2.73 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue was up .5% compared to the same quarter last year. During the same period last year, the company earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This is a boost from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio is currently 33.67%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.